You are here:
  1. Home
  2. About us
LinkedIn-button

About us

About
Intravacc

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc, part of the Utrecht Science Park location Bilthoven, is one of the world’s leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

LEARN MOREANNUAL REPORT 2020
LinkedIn-button

Our Vision

To reduce human diseases through innovative vaccine technology

LinkedIn-button

Our Mission

To partner with governmental
agencies, NGO's and private entities
to help to reduce the burden of diseases

LinkedIn-button

Intravacc to the point

  • Founded in 2013
  • HQ at Utrecht Science Park Bilthoven
  • Experts in vaccinology
  • Clinical development & manufacturing organization
  • 2000+ m2 state-of the art facilities, incl BSL-2/3 & GMP
  • ISO 14001 certified
  • >120 high qualified employees
  • 50+ customers worldwide
  • 300+ scientific publications in peer reviewed journals
BOARD OF DIRECTORS
MANAGEMENT TEAM
SUPERVISORY BOARD
SCIENTIFIC ADVISORY BOARD
LinkedIn-button

About us

Certifications

Intravacc performs her activities in compliance with applicable laws and regulations.

The care for employees and for the environment is a top priority for Intravacc. Sustainability is important to guarantee a safe and health environment for the future. Therefore, Intravacc implemented an environmental management system according to ISO 14001.

An external company regularly audits the management systems for ISO 14001 to assure continuously compliance.

For the manufacturing and quality control of clinical trial materials, Intravacc B.V. has a manufacturing license granted by the Dutch Authorities. Regular inspections are performed by the Dutch Inspectorate of Health to verify compliance.

ISO 14001 certificate
GMP manufacturer’s license
LinkedIn-button

About us

Latest News

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology and adjuvants   Bilthoven, The Netherlands, 23 February 2023 –  Intravacc, a world leader in…

The University of Strathclyde in Glasgow is recognized as a leading international technological university. The appointment of Prof. Schijns will be in the context to further strengthen the pharmacy & biomedical sciences education and research capabilities. During his three years assignment as Visiting Professor Schijns, will teach several courses. He will partake in research discussions and speak during lectures on the relevant areas, as well as participate in series of engagements with students, and academic colleagues.
Read more

Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection

• Global incidence rate of this sexual transmitted disease is at 87 million infections per year

• OMV technology is a powerful tool to induce protective systemic and mucosal immunity

• Data published in the peer reviewed journal MSphere of the American Society of Microbiology

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal immunity • Data published in the peer reviewed journal MSphere of the American Society of Microbiology
Read more
LinkedIn-button

About us

Media

LinkedIn-button

About us

Join our Community

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

VIEW OPEN POSITIONS

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.